CID16020046
Congenital Insensitivity to Pain with Anhidrosis (CIPA)[edit | edit source]
Congenital Insensitivity to Pain with Anhidrosis (CIPA), also known as Hereditary Sensory and Autonomic Neuropathy Type IV (HSAN IV), is a rare autosomal recessive disorder characterized by the inability to feel pain and temperature, along with decreased or absent sweating (anhidrosis). This condition is caused by mutations in the NTRK1 gene, which is crucial for the development and function of nerve cells that transmit pain, temperature, and autonomic signals.
Clinical Features[edit | edit source]
Individuals with CIPA are unable to perceive pain, which can lead to repeated injuries, burns, and other trauma that go unnoticed. The lack of pain sensation is often accompanied by anhidrosis, which can result in hyperthermia due to the body's inability to regulate temperature through sweating. Other features may include:
- Intellectual disability
- Self-mutilation behaviors
- Joint deformities due to repeated injuries
- Infections due to unnoticed injuries
Pathophysiology[edit | edit source]
CIPA is caused by mutations in the NTRK1 gene, which encodes the neurotrophic tyrosine kinase receptor type 1. This receptor is essential for the survival and function of nociceptive neurons and sympathetic neurons. The absence or dysfunction of these neurons leads to the clinical manifestations of CIPA.
Diagnosis[edit | edit source]
Diagnosis of CIPA is based on clinical evaluation, family history, and genetic testing to identify mutations in the NTRK1 gene. A skin biopsy may show the absence of nerve fibers responsible for pain and temperature sensation.
Management[edit | edit source]
Management of CIPA focuses on preventing injuries and managing complications. This includes:
- Regular monitoring for injuries and infections
- Protective measures to prevent trauma
- Management of hyperthermia through environmental control
- Multidisciplinary care involving neurologists, orthopedic surgeons, and psychologists
Prognosis[edit | edit source]
The prognosis for individuals with CIPA varies. While the condition itself is not life-threatening, complications from injuries and infections can significantly impact quality of life and life expectancy.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD